Ci Gaban Magungunan COVID-19

Ci Gaban Magungunan COVID-19
drug development (en)
Bayanai
Has goal (en)	treatment of COVID-19 (en)

COVID-19 miyagun ƙwayoyi ci gaba ne na bincike tsari wajen samar da preventative warkewa sayen magani kwayoyi da cewa zai rage tsananin coronavirus cuta 2019 (COVID-19). Daga farkon shekarar 2020 zuwa shekarar 2021, kamfanoni ɗari da yawa na magunguna, kamfanonin fasahar kere kere, ƙungiyoyin bincike na jami'a, da kuma ƙungiyoyin kiwon lafiya suna haɓaka ƴan takarar warkewa don cutar COVID-19 a matakai daban-daban na bincike na asali ko na asibiti (jimillan yan takara 506 a cikin Afrilun shekarar 2021), tare da yuwuwar 419. Magungunan COVID-19 a cikin gwaji na asibiti, har zuwa Afrilu 2021.^[1]

Kamar yadda a farkon Maris din shekarar 2020, da World Health Organization (WHO),^[2] Turai Magunguna Agency (Ema),^[3] Amurka Food and Drug Administration (FDA),^[4] kuma gwamnatin kasar Sin da kuma miyagun ƙwayoyi masana'antun^[5][6] sun kasance suna haɗin gwiwa tare da masu bincike na ilimi da masana'antu don haɓaka haɓakar rigakafi, magungunan rigakafi, da hanyoyin kwantar da hankali bayan kamuwa da cuta.^{[7][8][9][10]} Platform Registry Platform na Clinical Trials na WHO ya rubuta karatun asibiti 536 don haɓaka hanyoyin kwantar da hankali bayan kamuwa da cuta don cututtukan COVID-19,^[11][12] tare da kafaffen magungunan rigakafi da yawa don kula da wasu cututtuka a ƙarƙashin binciken asibiti don sake dawowa,^{[13][14][15][16]}

A cikin Maris din shekarar 2020, WHO ta ƙaddamar da " Gwajin SOLIDARITY " a cikin ƙasashe 10, tare da yin rajistar dubunnan mutanen da suka kamu da COVID-19 don tantance tasirin jiyya na mahaɗan rigakafin ƙwayoyin cuta guda huɗu tare da mafi girman alƙawarin inganci.^[2][16]An kafa bita mai ƙarfi, mai tsauri a cikin Afrilu 2020 don bin diddigin ci gaban gwajin asibiti da aka yi rajista don rigakafin COVID-19 da ƴan takarar magungunan warkewa.^[12]

Ci gaban ƙwayoyi tsari ne na matakai da yawa, yawanci yana buƙatar fiye da shekaru biyar don tabbatar da aminci da ingancin sabon fili.^[17] Hukumomin gudanarwa na ƙasa da yawa, kamar EMA da FDA, sun amince da hanyoyin don hanzarta gwajin asibiti.^[4][18] A watan Yuni 2021, da yawa yuwuwar hanyoyin warkewar kamuwa da cuta sun kasance a matakin ƙarshe na gwajin ɗan adam - gwaji na asibiti na Phase III-IV^[19] Ingantacciyar magani, dacewa ta COVID-19 na iya kaiwa tallace-tallace na shekara-shekara sama da dala biliyan 10, a cewar wani kiyasin Jefferies & Co na baya- bayan nan.^[20]

1. ↑ "COVID-19 vaccine and therapeutics tracker". BioRender. 5 April 2021. Retrieved 21 June 2021.
2. ↑ ^{2.0 2.1} Kupferschmidt K, Cohen J (22 March 2020). "WHO launches global megatrial of the four most promising coronavirus treatments". Science Magazine. doi:10.1126/science.abb8497. S2CID 216325781. Retrieved 27 March 2020.
3. ↑ "First regulatory workshop on COVID-19 facilitates global collaboration on vaccine development". European Medicines Agency. 18 March 2020. Retrieved 21 March 2020.
4. ↑ ^{4.0 4.1} "Coronavirus (COVID-19) Update: FDA Continues to Facilitate Development of Treatments" (Press release). U.S. Food and Drug Administration (FDA). 19 March 2020. Retrieved 21 March 2020.
5. ↑ "China approves first anti-viral drug against coronavirus Covid-19". Clinical Trials Arena. 18 February 2020. Retrieved 21 March 2020.
6. ↑ "Chinese Vaccine Approved for Human Testing at Virus Epicenter". Bloomberg News. 19 March 2020. Retrieved 21 March 2020.
7. ↑ Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (June 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics. 16 (6): 1232–1238. doi:10.1080/21645515.2020.1735227. PMC 7103671. PMID 32186952.
8. ↑ Zhang L, Liu Y (May 2020). "Potential interventions for novel coronavirus in China: A systematic review". Journal of Medical Virology. 92 (5): 479–490. doi:10.1002/jmv.25707. PMC 7166986. PMID 32052466.
9. ↑ Fox M (19 March 2020). "Drug makers are racing to develop immune therapies for Covid-19. Will they be ready in time?". Stat. Retrieved 21 March 2020.
10. ↑ Chan M (19 March 2020). "Chinese military scientists ordered to win global race to develop coronavirus vaccine". South China Morning Post. Retrieved 22 March 2020.
11. ↑ COVID-19 Clinical Research Coalition (April 2020). "Global coalition to accelerate COVID-19 clinical research in resource-limited settings". Lancet. 395 (10233): 1322–1325. doi:10.1016/s0140-6736(20)30798-4. PMC 7270833. PMID 32247324.
12. ↑ ^{12.0 12.1} Maguire BJ, Guérin PJ (2 April 2020). "A living systematic review protocol for COVID-19 clinical trial registrations". Wellcome Open Research. 5: 60. doi:10.12688/wellcomeopenres.15821.1. PMC 7141164. PMID 32292826.
13. ↑ Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (June 2020). "COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics". Human Vaccines & Immunotherapeutics. 16 (6): 1232–1238. doi:10.1080/21645515.2020.1735227. PMC 7103671. PMID 32186952.
14. ↑ Li G, De Clercq E (March 2020). "Therapeutic options for the 2019 novel coronavirus (2019-nCoV)". Nature Reviews. Drug Discovery. 19 (3): 149–150. doi:10.1038/d41573-020-00016-0. PMID 32127666.
15. ↑ Dong L, Hu S, Gao J (29 February 2020). "Discovering drugs to treat coronavirus disease 2019 (COVID-19)". Drug Discoveries & Therapeutics. 14 (1): 58–60. doi:10.5582/ddt.2020.01012. PMID 32147628.
16. ↑ ^{16.0 16.1} Harrison C (April 2020). "Coronavirus puts drug repurposing on the fast track". Nature Biotechnology. 38 (4): 379–381. doi:10.1038/d41587-020-00003-1. PMID 32205870.
17. ↑ "The Drug Development Process". U.S. Food and Drug Administration (FDA). 4 January 2018. Retrieved 21 March 2020.
18. ↑ "Call to pool research resources into large multi-centre, multi-arm clinical trials to generate sound evidence on COVID-19 treatments". European Medicines Agency. 19 March 2020. Retrieved 21 March 2020.
19. ↑ Cite error: Invalid <ref> tag; no text was provided for refs named milken2
20. ↑ Beasley, Deena (28 September 2021). "COVID-19 pill developers aim to top Merck, Pfizer efforts". Reuters (in Turanci). Reuters.